Initial Public Offering
Baird served as a book-running manager on this offering
AboutMaravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI), a portfolio company of GTCR, LLC (“GTCR”), recently completed an initial public offering of 69,000,000 shares of its Class A common stock at $27.00 per share, generating gross proceeds of approximately $1,863 million, which included the exercise in full by the underwriters of their option to purchase 9,000,000 additional shares of Class A common stock on the same terms and conditions.
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. Maravai LifeSciences Holdings, Inc. is headquartered in San Diego, California.
Founded in 1980, GTCR is a leading growth-oriented private equity firm focused on investing in growth companies in the Healthcare, Financial Services & Technology, Technology, Media & Telecommunications and Growth Business Services industries. GTCR pioneered The Leaders Strategy™—finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Maravai is an example of the Leaders Strategy™, whereby GTCR is partnering with Carl Hull and Eric Tardif to build and grow a leading life sciences platform. Since its inception, GTCR has invested more than $18 billion in over 200 companies. GTCR is headquartered in Chicago, Illinois.
CONTACT US TO LEARN MORE
- November 2020
- Maravai LifeSciences Holdings, Inc.
- Target Location
- North America